Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference

Rhea-AI Summary

Marinus Pharmaceuticals (Nasdaq: MRNS) announced its participation in two key investment conferences. Management will present at the H.C. Wainwright Bioconnect Conference on January 10, at 7:00 a.m. ET, featuring CEO Scott Braunstein and CFO Steven Pfanstiel. The 40th Annual J.P. Morgan Healthcare Conference is scheduled for January 13, at 8:15 a.m. ET, also with Scott Braunstein presenting. Both events will be available via webcast, allowing stakeholders to engage with the company's mission in treating seizure disorders.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that company management will present virtually during the H.C. Wainwright Bioconnect Conference as well as the 40th Annual J.P. Morgan Healthcare Conference.

Webcast details can be found below:

H.C. Wainwright Bioconnect 2022 Conference

• Date/Time: Available on demand Monday, January 10 at 7:00 a.m. ET
• Speakers: Scott Braunstein, M.D., Chief Executive Officer, and Steven Pfanstiel, Chief Financial Officer
• Webcast Link: https://journey.ct.events/view/6992c37e-b03f-44f3-bc70-993d1d54f6a9

40th Annual J.P. Morgan Healthcare Conference

• Date/Time: Thursday, January 13 at 8:15 a.m. ET
• Speaker: Scott Braunstein, M.D., Chief Executive Officer
• Audio Webcast Link: https://jpmorgan.metameetings.net/events/healthcare22/sessions/40628-marinus-pharmaceuticals-inc/webcast?gpu_only=true&kiosk=true

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABA_A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005288/en/

Sasha Damouni Ellis

Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

484-253-6792

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals

FAQ

What is Marinus Pharmaceuticals announcing on January 10, 2022?

Marinus Pharmaceuticals will present virtually at the H.C. Wainwright Bioconnect Conference on January 10, 2022, at 7:00 a.m. ET.

When is the 40th Annual J.P. Morgan Healthcare Conference for Marinus Pharmaceuticals?

The 40th Annual J.P. Morgan Healthcare Conference will take place on January 13, 2022, at 8:15 a.m. ET.

Who will represent Marinus Pharmaceuticals at the investment conferences?

CEO Scott Braunstein and CFO Steven Pfanstiel will represent Marinus Pharmaceuticals at the H.C. Wainwright Bioconnect Conference.

Where can I find the webcast for Marinus Pharmaceuticals' presentations?

The webcasts for Marinus Pharmaceuticals' presentations can be accessed via the conference links provided in their press release.

What is the focus of Marinus Pharmaceuticals?

Marinus Pharmaceuticals focuses on developing innovative therapeutics for treating seizure disorders, including the drug Ganaxolone.